# CYP1A2 DDI Qualification

| Version                         | 1.0-OSP12.0                                                   |
| ------------------------------- | ------------------------------------------------------------ |
| Qualification Plan Release      | https://github.com/Open-Systems-Pharmacology/Qualification-DDI-CYP1A2/releases/tag/v1.0 |
| OSP Version                     | 12.0                                                          |
| Qualification Framework Version | 3.3                                                          |

This qualification report is filed at:

https://github.com/Open-Systems-Pharmacology/OSP-Qualification-Reports

# Table of Contents

 * [1 1 Introduction](#1)

# 1 1 Introduction<a id="1"></a>

                   

<a id="figure-1-1"></a>

![](images/001_section_1/DDIRatio_1_ddi_ratio_plot_AUC_predictedVsObserved.png)

**Figure 1-1: CYP1A2 DDI.  Predicted vs. Observed AUC Ratio. (&delta; = 1 in Guest *et al.* formula)**

<br>
<br>

<a id="figure-1-2"></a>

![](images/001_section_1/DDIRatio_1_ddi_ratio_plot_AUC_residualsVsObserved.png)

**Figure 1-2: CYP1A2 DDI.  Predicted/Observed vs. Observed AUC Ratio. (&delta; = 1 in Guest *et al.* formula)**

<br>
<br>

<a id="figure-1-3"></a>

![](images/001_section_1/DDIRatio_1_ddi_ratio_plot_CMAX_predictedVsObserved.png)

**Figure 1-3: CYP1A2 DDI.  Predicted vs. Observed CMAX Ratio. (&delta; = 1 in Guest *et al.* formula)**

<br>
<br>

<a id="figure-1-4"></a>

![](images/001_section_1/DDIRatio_1_ddi_ratio_plot_CMAX_residualsVsObserved.png)

**Figure 1-4: CYP1A2 DDI.  Predicted/Observed vs. Observed CMAX Ratio. (&delta; = 1 in Guest *et al.* formula)**

<br>
<br>

<a id="table-1-1"></a>

**Table 1-1: GMFE for CYP1A2 DDI Ratio**

|PK parameter |GMFE |
|:------------|:----|
|AUC          |3.15 |
|CMAX         |1.04 |

<br>
<br>

<a id="table-1-2"></a>

**Table 1-2: Summary table for CYP1A2 DDI - AUC Ratio. (&delta; = 1 in Guest *et al.* formula)**

|AUC                          |Number |Ratio [%] |
|:----------------------------|:------|:---------|
|Points total                 |1      |-        |
|Points within Guest *et al.* |0      |0         |
|Points within 2 fold         |0      |0         |

<br>
<br>

<a id="table-1-3"></a>

**Table 1-3: Summary table for CYP1A2 DDI - CMAX Ratio. (&delta; = 1 in Guest *et al.* formula)**

|CMAX                         |Number |Ratio [%] |
|:----------------------------|:------|:---------|
|Points total                 |1      |-        |
|Points within Guest *et al.* |1      |100       |
|Points within 2 fold         |1      |100       |

<br>
<br>

<a id="table-1-4"></a>

**Table 1-4: Summary table for CYP1A2 DDI**

|DataID |Perpetrator              |Victim       |Predicted AUC Ratio |Observed AUC Ratio |Pred/Obs AUC Ratio |Predicted CMAX Ratio |Observed CMAX Ratio |Pred/Obs CMAX Ratio |Reference        |
|:------|:------------------------|:------------|:-------------------|:------------------|:------------------|:--------------------|:-------------------|:-------------------|:----------------|
|14006  |Fluvoxamine, 100 mg, PO, |Caffeine, PO |4.35                |13.71              |0.32               |1.34                 |1.40                |0.96                |Culm-Merdek 2005 |

<br>
<br>

<a id="figure-1-5"></a>

![](images/001_section_1/comparison_time_profile_Culm_Merdeck_2005__Caffeine_250_mg_po__1.png)

**Figure 1-5: Culm-Merdeck 2005 (Caffeine 250 mg po)**

<br>
<br>

